CAMP4 Therapeutics Corporation

GlobeNewsWire•7/27/2026

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

GlobeNewsWire•7/17/2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Globe News Wire•7/17/2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research•7/16/2026

New Strong Sell Stocks for July 16th

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

GlobeNewsWire•6/19/2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

Globe News Wire•6/19/2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the "Inducement Grants").

GlobeNewsWire•6/16/2026

Discovr Radio to Embed Across All Four Days of CAMP Toronto in First Major Activation with Beatcave

Live demo listening session to approve artists onto the platform in real time New “golden ticket” subscriptions reward breakout performers on the spot Studio takeover and on-site activations give creators direct access to Discovr Radio's AI powered artist promotion tools BOULDER, Colo., June 16, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio and how artists get discovered, today announced that its Discovr Radio AI powered artist promotion platform will integrate across all four days of CAMP Toronto, the flagship songwriting camp and music conference hosted by partner Beatcave, taking place July 16-19, 2026.

GlobeNewsWire•6/8/2026

New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity

Canadian GoldCamps says Mercator resampling returned gold in 82% of samples, confirming mineralization continuity and new high-grade targets for 2026 work.

TheNewswire•5/26/2026

Mercator Gold Exploration Priorities & Strategy

Company to advance NI 43-101 Technical Report; 2026 exploration campaign to follow up on promising historic work including high-grade intercepts of 5.6 metres of 4.87 g/t gold Vancouver, British Columbia, TheNewswire, May 26, 2026, Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to provide an update on its 2026 exploration strategy for the Mercator and Courcy gold projects located in the Caniapiscau district of northeastern Québec.

GlobeNewsWire•5/21/2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

GlobeNewsWire•5/14/2026

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model